QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 zyversa-highlights-review-of-172-studies-linking-lipotoxicity-to-dkd-progression-supports-therapeutic-targeting-of-lipid-metabolic-reprogramming

Data show that diabetes-associated metabolic issues lead to kidney lipid accumulation, resulting in inflammation and fibrosis t...

 zyversa-therapeutics-q2-eps-046-misses-040-estimate

ZyVersa Therapeutics (NASDAQ:ZVSA) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate o...

 zyversa-therapeutics-releases-mid-year-shareholder-letter-highlighting-recent-corporate-developments-and-rd-progress-including-closing-two-financial-transactions-providing-access-to-12m-in-capital

 ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing...

 why-did-zyversa-therapeutics-stock-shoot-higher-on-tuesday

ZyVersa gains FDA approval for emergency use of VAR 200 in a rare kidney disease case; stock jumps on high trading volume and r...

 zyversa-therapeutics-enters-2m-warrant-inducement-deal-issues-new-series-a-4-warrants-for-61m-shares-at-067-exercise-price

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing ...

 zyversa-therapeutics-provides-regulatory-and-product-support-for-fda-authorized-emergency-compassionate-use-of-cholesterol-efflux-mediator-var-200-in-apocii-amyloidosis-patient

ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition th...

 zyversa-therapeutics-announces-first-clinical-site-activation-initiates-patient-recruitment-for-cholesterol-efflux-mediator-var-200s-phase-2a-clinical-trial-in-patients-with-dkd

Initiation of patient recruitment marks a key milestone in the development of VAR 200, a potential first-in-class treatment for...

 zyversa-therapeutics-enters-into-spa-for-up-to-10m-in-partnership-with-williamsburg-venture-holdings-to-fund-clinical-development-of-cholesterol-efflux-mediator-var-200

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing ...

 zyversa-therapeutics-highlights-newly-published-data-further-substantiating-potential-of-inflammasome-asc-inhibitor-ic-100-as-disease-modifying-treatment-for-pd

Study results corroborate our recently published data demonstrating the critical role of microglial-driven inflammation in prom...

 zyversa-therapeutics-q1-eps-073-misses-040-estimate

ZyVersa Therapeutics (NASDAQ:ZVSA) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION